ERBB2 and breast neoplasm: The HER2 status assessment was establishment by The American Society of Clinical Oncology and the College of American Pathologists (ASCO/CAP), with the publication of guidelines with recommendations for testing the level of HER2 protein overexpression by IHC and the HER2 gene amplification determined by ISH, both on FFPE breast tumor tissues.